DIM for PCOS: What Diindolylmethane Does and Why the PCOS Evidence Is Thin

Is There Any PCOS Trial Evidence for DIM?

Zero randomised trials have tested DIM in women with PCOS. The two human studies that exist were both done in postmenopausal women, for reasons that have nothing to do with PCOS: one studied breast-cancer survivors’ urinary hormone metabolites, the other studied an interaction with prescribed hormone-replacement therapy. Neither measured testosterone, ovulation, hirsutism, acne, or any outcome that defines PCOS. This is the single most important thing to know before spending money on a DIM supplement for PCOS — the recommendation you’re reading elsewhere is not backed by a PCOS trial, because one has not been run.

What DIM Is Supposed to Do

DIM is the primary compound your body produces when you digest indole-3-carbinol, a substance found in cruciferous vegetables like broccoli, cabbage and Brussels sprouts. Inside the liver, DIM activates a receptor that switches on two enzymes — CYP1A1 and CYP1A2 — which process oestrogen down one particular metabolic pathway instead of another. In laboratory conditions, 50 micromolar DIM induced these enzymes in cultured human liver tissue, with the size of the effect varying widely — from roughly 2-fold to more than 19-fold — between individual liver samples tested.

The theory sold alongside DIM supplements is that shifting oestrogen metabolism this way “balances hormones” in a way relevant to PCOS. That theory has a real biochemical basis. It has not been tested in anyone with PCOS.

The 2004 Pilot Study, With the Actual Numbers

Ten postmenopausal breast-cancer survivors took 108 mg of DIM daily for 30 days, compared against 9 on placebo, in the only trial that has directly dosed DIM and measured urinary oestrogen metabolites in humans. One specific metabolite, 2-hydroxyestrone, rose significantly (p=0.02). The ratio the marketing usually cites — 2-hydroxyestrone to 16-alpha-hydroxyestrone — rose 47%, from 1.46 to 2.14, but that change did not reach statistical significance (p=0.059).

Two things about this trial matter more than the numbers. First, it enrolled 19 women total — too small to be conclusive about anything. Second, and more importantly, every participant was postmenopausal, meaning ovarian oestrogen production had already stopped. Nothing about how DIM behaves in a postmenopausal breast-cancer survivor tells you how it would behave in a premenopausal person with PCOS, whose ovaries are actively producing hormones and whose problem is usually excess androgen, not excess oestrogen.

The 2025 Study: A Real Effect, Still Not PCOS

A retrospective study of 1,458 postmenopausal women using a transdermal estradiol patch found that the 108 of them also taking a DIM supplement had significantly different urinary oestrogen profiles than the women on the patch alone — 6 of 10 measured metabolites differed, all at p < 0.001, including the same 2-OHE1/16-OHE1 ratio.

This is the strongest evidence that DIM does something measurable to oestrogen metabolism in real-world use. It is also, again, not a PCOS study: it was observational rather than randomised, conducted entirely in postmenopausal women on prescribed hormone therapy, and its purpose was to flag a possible drug-supplement interaction — not to test a PCOS outcome.

Regulatory Status and Why the Dose You Get May Not Match the Label

DIM is sold as a dietary supplement, not a drug, which means it is not required to prove efficacy before sale and is not held to the same manufacturing and potency standards as a prescription medicine. The one trial that dosed DIM precisely used a specific pharmaceutical preparation (BioResponse-DIM) at 108 mg daily — a controlled-release formulation designed for better absorption. An over-the-counter DIM product bought without checking its formulation may deliver a meaningfully different amount of active compound than what any study has tested, even at the same milligram number on the label.

Interactions Worth Knowing

Because DIM induces CYP1A2, an enzyme that helps clear certain other drugs from the body, it has the theoretical potential to change how those drugs are metabolised — the same enzyme processes some medications for depression, anxiety, and irregular heart rhythm, along with caffeine. Separately, because the 2025 study found DIM measurably altering the oestrogen profile of women on prescribed hormone therapy, the same interaction is plausible with hormonal contraceptives or any oestrogen-containing PCOS treatment. Neither interaction has been formally tested as a clinical trial outcome — the evidence is mechanistic (the enzyme induction) plus one observational signal (the 2025 cohort) — which is exactly why it is worth mentioning to a prescriber or pharmacist rather than assuming it is safe to combine silently.

You may also see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the evidence gap above changes under either name — this article uses PCOS because that is still what people search.

Who This Won’t Help

Measured against the rest of this site’s supplements and medications section, DIM is one of the weakest-evidenced options covered. It will not help:

• Anyone looking for a PCOS-trial-backed option. DIM does not have one. The 2023 international PCOS guideline was built by reviewing the trial evidence behind PCOS treatments — and for DIM, as shown above, that trial evidence in PCOS does not exist to review.
• Anyone hoping to lower testosterone specifically. No study has measured whether DIM does this in anyone, PCOS or otherwise. If lowering androgen-driven symptoms is the goal, high testosterone in women covers what actually has trial evidence behind it.
• Anyone on hormonal medication who hasn’t checked with a prescriber first — see the interactions section above.
• Anyone premenopausal expecting the postmenopausal data to transfer. Both existing human studies were done in women whose ovaries were no longer producing hormones, which is the opposite hormonal situation from PCOS.

Two other botanicals get compared to DIM for PCOS, and both have thin but real evidence, unlike DIM’s near-total absence of it: spearmint tea has two small trials that moved blood testosterone, and vitex has one PCOS-specific trial plus a larger body of PMS and hyperprolactinaemia research. For where all three rank against options with real PCOS trial evidence, like inositol and vitamin D, see the evidence-ranked supplements guide.

Common questions